Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Merck
McKesson
Boehringer Ingelheim
Colorcon
McKinsey

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

XALKORI Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Xalkori patents expire, and when can generic versions of Xalkori launch?

Xalkori is a drug marketed by Pf Prism Cv and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and forty-five patent family members in forty-seven countries.

The generic ingredient in XALKORI is crizotinib. One supplier is listed for this compound. Additional details are available on the crizotinib profile page.

Drug patent expirations by year for XALKORI
Drug Prices for XALKORI

See drug prices for XALKORI

Generic Entry Opportunity Date for XALKORI
Generic Entry Date for XALKORI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XALKORI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University Health Network, TorontoPhase 2
Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyPhase 2/Phase 3
PfizerPhase 4

See all XALKORI clinical trials

Synonyms for XALKORI
(R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-am ine
(R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine
(R)-crizotinib
2-Pyridinamine, 3-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(4-piperidinyl)-1H-pyrazol-4-yl)-
3-((1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(4-piperidinyl)-1h-pyrazol-4-yl)pyridin-2-amine
3-(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy-5-1-(4-piperidinyl)-1H-pyrazol-4-yl-2-Pyridinamine
3-[(1r)-1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-5-(1-Piperidin-4-Yl-1h-Pyrazol-4-Yl)pyridin-2-Amine
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[
3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine
3-[(1R)-1-(2,6-DICHLORO-3-FLUOROPHENYL)ETHOXY]-5-[1-(4-PIPERIDINYL)-1H-PYRAZOL-4-YL]PYRIDIN-2-AMINE
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine
3-[(R)-1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine
399P525
53AH36668S
877399-52-5
877399-52-5, 877399-53-6 (acetate)
912279-98-2
AB0027203
ABP000131
AK172044
AKOS015901233
AKOS015995207
AMX10152
ANW-47749
AOB2688
BB 0261738
BC622990
BCPP000116
BDBM50306682
BRD-K78431006-001-01-1
BRD-K78431006-001-03-7
C21H22Cl2FN5O
CHEBI:64310
CHEMBL601719
Crizotinib
Crizotinib (JAN/USAN/INN)
Crizotinib (PF-02341066)
Crizotinib (PF-2341066)
Crizotinib [USAN:INN]
Crizotinib, >=98% (HPLC)
Crizotinib; PF 2341066
crizotinibum
CTK5F8952
D09731
DB08865
EN002685
EX-A096
FT-0665224
GS-6178
GTPL4903
HY-50878
I14-14837
J-510370
KB-26391
KIN0000318
KS-0000075X
KTEIFNKAUNYNJU-GFCCVEGCSA-N
MolPort-009-679-404
NCGC00250400-01
NCGC00250400-09
NCGC00250400-12
NSC-749005
NSC749005
PB11015
PF 02341066
PF 2341066
PF 2341066;(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine
PF-02341066
PF-02341066 (Crizotinib)
PF-2341066
PF-2341066 - Crizotinib
PF-2341066 (Crizotinib)
PF-2341066,Crizotinib
PF-2341066(Crizotinib)
PF2341066
PubChem19322
Q-3209
QCR-32
RL05464
SC-48062
SCHEMBL93829
SW202555-3
SYN1139
TX-017903
UNII-53AH36668S
VGH
W9013
Xalkori (TN)
ZINC35902489

US Patents and Regulatory Information for XALKORI

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-001 Aug 26, 2011 RX Yes No   Start Trial   Start Trial Y   Start Trial
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-002 Aug 26, 2011 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-001 Aug 26, 2011 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-002 Aug 26, 2011 RX Yes Yes   Start Trial   Start Trial   Start Trial
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-002 Aug 26, 2011 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for XALKORI

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1786785 13C0015 France   Start Trial PRODUCT NAME: CRIZOTINIB ET SES SELS, HYDRATES ET SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/793/001 20121023
1786785 PA2013005 Lithuania   Start Trial PRODUCT NAME: CRIZOTINIBUM; REGISTRATION NO/DATE: EU/1/12/793/001 - EU/1/12/793/004 20121023
1786785 1390008-9 Sweden   Start Trial PRODUCT NAME: CRIZOTINIB INKLUSIVE ETT FARMACEUTISKT GODTAGBART SALT, SOLVAT ELLER HYDRAT DAERAV; REG. NO/DATE: EU/1/12/793/001 20121023; PERIOD OF VALIDITY (FROM - UNTIL): 2025-08-16 - 2027-10-25
1786785 SPC/GB13/018 United Kingdom   Start Trial PRODUCT NAME: CRIZOTINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF.; REGISTERED: UK EU/1/12/793/001 20121026; UK EU/1/12/793/002 20121026; UK EU/1/12/793/003 20121026; UK EU/1/12/793/004 20121026
1786785 C20130007 00075 Estonia   Start Trial PRODUCT NAME: KRISOTINIIB;REG NO/DATE: K(2012)7617 LOPLIK 23.10.2012
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
McKinsey
McKesson
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.